Platinum-based systematic therapy in triple-negative breast cancer

Area of Science:

• Oncology
• Medical Chemistry

Background:

• Triple-negative breast cancer (TNBC) lacks hormone receptors, limiting targeted therapy options.
• Current chemotherapy (taxanes/anthracyclines) faces challenges like cardiotoxicity and drug resistance.
• Platinum-based chemotherapy is emerging as a viable treatment strategy for TNBC.

Purpose of the Study:

• To review clinical trials on platinum-based regimens for TNBC.
• To assess platinum monotherapy and combination treatments.
• To analyze biomarkers for predicting platinum response in TNBC patients.

Main Methods:

• Literature review of clinical trials involving platinum agents (cisplatin, carboplatin, oxaliplatin).
• Analysis of studies combining platinum with chemotherapy, targeted therapy, or immunotherapy.
• Evaluation of biomarkers including BRCA1/2, HRD, TILs, TP53, CDK2, VEGF, and MMP-9.

Main Results:

• Accumulating studies show potential for platinum-containing regimens in TNBC treatment.
• Biomarker analysis is crucial for identifying patients who will benefit most from platinum therapy.
• Further research is needed to optimize platinum-based strategies and patient selection.

Conclusions:

• Platinum-based chemotherapy represents a significant advancement in TNBC treatment.
• Biomarker-driven approaches are essential for maximizing the efficacy of platinum therapy.
• Personalized treatment strategies incorporating platinum agents hold promise for improving TNBC patient outcomes.